Momenta's Momentous Event
Sanofi Circling Wagons After FDA Clears Generic Lovenox
By Randy Osborne
Monday, August 2, 2010
Momenta Pharmaceuticals Inc.'s surprising good fortune with the FDA's nod last week for the company's generic Lovenox sent shares skyrocketing 82 percent and capped five years of exchanges between the regulatory agency and Momenta with partner Sandoz, the generic unit of Basel, Switzerland-based Novartis AG. It also may have sent an ominous signal to Teva Pharmaceuticals Inc.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.